



**Department of Vermont Health Access  
Pharmacy Benefits Management Program  
*DUR Board Meeting Agenda***

---

**February 19, 2013 6:00 – 8:30 p.m.**

- 1. Executive Session 6:00 - 6:30**
  - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))
  
- 2. Introductions and Approval of DUR Board Minutes 6:30 - 6:35**

(Public Comment Prior to Board Action)
  
- 3. DVHA Pharmacy Administration Updates 6:35 - 6:45**
  - Updates
  
- 4. Medical Director Update 6:45 - 6:45**
  - Clinical Programs Update
  - Prescriber Comments
  
- 5. Follow-up Items from Previous Meetings 6:45 - 7:00**
  - Skeletal Muscle Relaxants
  - Gastrointestinal: Anti-ulcer: H.Pylori Combination Therapy
  
- 6. RetroDUR/DUR 7:00 – 7:30**
  - Methadone for Chronic Pain
  - Narcotic Analgesics – continued use of short acting with no long acting
  
- 7. Clinical Update: Drug Reviews 7:30 – 7:55**

(Public comment prior to Board action)

**Abbreviated New Drug Reviews**

  - Gelnique<sup>®</sup> 3% (oxybutynin 3% gel) 84 mg/3 pump actuations
  - Rectiv<sup>®</sup> (nitroglycerin 0.4%) Topical Ointment
  - Sorilux<sup>®</sup> (calcipotriene 0.005%) Topical Foam

**Full New Drug Reviews**

  - Myrbetriq<sup>®</sup> (mirabegron) Extended Release Tablet
  - Tudorza<sup>®</sup> Pressair (aclidinium bromide) Dry Powder Inhaler

- 8. Therapeutic Drug Classes – Periodic Review** **7:55 – 8:20**  
(Public comment prior to Board action)  
**Class review documents available on DVHA web site 02/19/2013 @ 12 Noon**
- Antiemetics – 5HT<sub>3</sub> Receptor Antagonists & Neurokinin 1 Receptor Antagonist
  - Antiemetics - Delta-9-Tetrahydrocannabinol (THC) Derivatives
  - Benign Prostatic Hyperplasia Agents
  - Erythropoiesis Stimulating Agents
  - Ophthalmic Alpha-Agonists
  - Ophthalmic Carbonic Anhydrase Inhibitors
  - Urinary Antispasmodics
- 9. New Managed Therapeutic Drug Classes** **8:20 – 8:20**  
(Public comment prior to Board action)
- None
- 10. Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products** **8:20 – 8:20**  
(Public comment prior to Board action)
- None
- 11. General Announcements** **8:20– 8:30**  
**Selected FDA Safety Alerts**
- Samsca<sup>®</sup> (tolvaptan): Drug Warning - Potential Risk of Liver Injury
  - Zolpidem Containing Products: Drug Safety Communication - FDA Requires Lower Recommended Doses
- 12. Adjourn** **8:30**